These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31167998)

  • 21. Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia.
    Pullarkat ST; Pullarkat V; Kroft SH; Wilson CS; Ahsanuddin AN; Mann KP; Thein M; Grody WW; Brynes RK
    J Hematop; 2009 Mar; 2(1):27-33. PubMed ID: 19669220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
    Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
    Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical Staining to Identify Concomitant Systemic Mastocytosis in Acute Myeloid Leukemia with
    Hwang SM; Kim BJ; Lee JS; Seong MW; Seo SH; Paik JH; Kim SA; Lee JY; Lee JO; Chang YH; Bang SM
    Ann Lab Med; 2022 Nov; 42(6):678-682. PubMed ID: 35765876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Impact of KIT D816 mutation on salvage therapy in relapsed acute myeloid leukemia with t(8;21) translocation].
    Gong BF; Tan YH; Liao AJ; Li J; Mao YY; Lu N; Ding Y; Jiang EL; Gong TJ; Jia ZL; Sun Y; Li BZ; Liu SC; Du J; Huang WR; Wei H; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):460-464. PubMed ID: 30032560
    [No Abstract]   [Full Text] [Related]  

  • 25. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.
    Schlenk RF; Kayser S
    Recent Results Cancer Res; 2018; 212():199-214. PubMed ID: 30069632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics and prognostic factors of acute myeloid leukemia with t (8; 21) (q22; q22).
    Lai YY; Qiu JY; Jiang B; Lu XJ; Huang XJ; Zhang Y; Liu YR; Shi HL; Lu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):733-40. PubMed ID: 16277833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic mastocytosis with an associated t(8;21)(q22;q22) acute myeloid leukemia.
    Wimmer J; Hurstel R
    Blood; 2021 May; 137(18):2564. PubMed ID: 33956065
    [No Abstract]   [Full Text] [Related]  

  • 28. Systemic Mastocytosis with Associated Hematological Neoplasms. Diagnostic features and unique response pattern to tyrosine kinase inhibitors and allo-bone marrow transplantation therapy.
    Hernández Alconchel I; González de Villambrosía S; Insunza Gaminde A; Montes Moreno S
    Rev Esp Patol; 2023; 56(3):180-185. PubMed ID: 37419556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
    Sly N; Gaspar K
    Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.
    Corless CL; Harrell P; Lacouture M; Bainbridge T; Le C; Gatter K; White C; Granter S; Heinrich MC
    J Mol Diagn; 2006 Nov; 8(5):604-12. PubMed ID: 17065430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical analysis of acute myeloid leukemia with t(8;21) (q22;q22) and loss of Y chromosome].
    Zhu CY; Yang H; Niu JH; Zhang Q; Xie XL; Wang LJ; Zhu HY; Yao ZL; Yu L; Jing Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):950-6. PubMed ID: 25130809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone.
    Pullarkat V; Bedell V; Kim Y; Bhatia R; Nakamura R; Forman S; Sun J; Senitzer D; Slovak ML
    Leuk Res; 2007 Feb; 31(2):261-5. PubMed ID: 16876862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clearance of bone marrow mast cells after hypomethylating agent and venetoclax for systemic mastocytosis associated with myeloid neoplasia.
    Pourhassan H; Kim Y; Pullarkat V
    Eur J Haematol; 2023 Feb; 110(2):213-216. PubMed ID: 36335580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child.
    Zheng Y; Nong L; Liang L; Wang W; Li T
    Diagn Pathol; 2018 Feb; 13(1):14. PubMed ID: 29458385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Heterogeneity of acute myeloid leukemia with the translocation t(8;21)(q22;q22)].
    Gritsaev SV; Martynkevich IS; Ziuzgin IS; Kariagina EV; Martynenko LS; Petrova EV; Tsybakova NIu; Ivanova MP; Kostroma II; Tiranova SA; Potikhonova NA; Abdulkadyrov KM
    Ter Arkh; 2014; 86(7):45-52. PubMed ID: 25314777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
    Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
    Stone RM; Manley PW; Larson RA; Capdeville R
    Blood Adv; 2018 Feb; 2(4):444-453. PubMed ID: 29487059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1.
    Pullarkat ST; Pullarkat V; Lagoo A; Brynes R; Weiss LM; Bedell V; Chen W; Huang Q; Gaal K; Weisenburger DD; Kim YS
    Leuk Res; 2013 Nov; 37(11):1572-5. PubMed ID: 24035334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature.
    Bernd HW; Sotlar K; Lorenzen J; Osieka R; Fabry U; Valent P; Horny HP
    J Clin Pathol; 2004 Mar; 57(3):324-8. PubMed ID: 14990611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.